1. Introduction {#sec1-marinedrugs-16-00517}
===============

Soft corals of the genus *Sinularia* (phylum Cnidaria, class Anthozoa, subclass Octocorallia, order Alcyonacea, suborder Alcyoniina, family Alcyoniidae), comprising more than 100 species, constitute an important invertebrate group occurring widely in different coral reefs of the world. The genus *Sinularia* is well known for being a rich source of valuable secondary metabolites as they have produced many structurally unique and biologically active compounds. Since 1975 \[[@B1-marinedrugs-16-00517],[@B2-marinedrugs-16-00517]\], over 50 species of the genus *Sinularia* have been chemically investigated, showing a wide range of structure diversities in diterpenes (especially cembrane diterpenes) \[[@B3-marinedrugs-16-00517],[@B4-marinedrugs-16-00517]\], sesquiterpenes \[[@B5-marinedrugs-16-00517],[@B6-marinedrugs-16-00517]\], polyhydroxylated steroids \[[@B7-marinedrugs-16-00517],[@B8-marinedrugs-16-00517]\], polyamines \[[@B9-marinedrugs-16-00517],[@B10-marinedrugs-16-00517]\], cyclopentenones \[[@B6-marinedrugs-16-00517],[@B8-marinedrugs-16-00517],[@B11-marinedrugs-16-00517],[@B12-marinedrugs-16-00517]\], and butenolides \[[@B11-marinedrugs-16-00517],[@B12-marinedrugs-16-00517]\]. Many of these metabolites exhibited a wide range of biological activities, including cytotoxic \[[@B13-marinedrugs-16-00517],[@B14-marinedrugs-16-00517]\], anti-inflammatory \[[@B15-marinedrugs-16-00517]\], antimicrobial \[[@B16-marinedrugs-16-00517]\], antifouling \[[@B17-marinedrugs-16-00517]\], and antifeedant activities \[[@B18-marinedrugs-16-00517]\].

Up to now, there have been few reports on the soft coral *S.* cf. *molesta* and *S. molesta*, except for one report on the Moyli Island *S. intacta* (a synonym of *S. molesta*) in 1999, resulting in a series of africane-type sesquiterpenes \[[@B19-marinedrugs-16-00517]\]. In addition, our first and preliminary study on *S.* cf. *molesta* yielded some terpenoids and sterols \[[@B20-marinedrugs-16-00517]\]. In our continuing interest in bioactive natural products from Paracel Islands invertebrates \[[@B8-marinedrugs-16-00517],[@B21-marinedrugs-16-00517],[@B22-marinedrugs-16-00517]\], we investigated extracts of the Paracel Islands soft coral *S.* cf. *molesta* that exhibited cytotoxic activities against human leukemia cell lines (K562) and human myeloid leukemia cell lines (HL-60), with the inhibition ratios of 60.0% and 72.8%, respectively, at the concentration of 50 μM. That led to the isolation of two new secoguaiane-type sesquiterpenes (**1** and **2**), three new guaiane-type sesquiterpenes (**3**--**5**), three new cyclopentenone derivatives ((+)-**9**--(+)-**11**), one new butenolide derivative ((+)-**13**), and one new furanocembranolide (**14**), together with 14 known analogs (**6**--**8**, (--)-**9**--(--)-**11**, (±)-**12**, (--)-**13**, and **15**--**19**) ([Figure 1](#marinedrugs-16-00517-f001){ref-type="fig"}). Their cytotoxic and inhibitory activities against protein tyrosine phosphatase 1B (PTP1B) were evaluated. Herein, we report the isolation, structure elucidation, and bioactivities of these compounds.

2. Results and Discussion {#sec2-marinedrugs-16-00517}
=========================

Molestin A (**1**) was obtained as a colorless oil. Its molecular formula of C~15~H~24~O~3~ was established through a protonated molecular \[M + H\]^+^ at *m*/*z* 253.1803 (calcd for C~15~H~25~O~3~, 253.1798) in the (+)-high-resolution electrospray ionization mass spectrometry (HRESIMS) spectrum, indicating four degrees of unsaturation. The infrared radiation (IR) spectrum displayed absorption bands for hydroxy (3151 cm^−1^), carbonyl (1712 cm^−1^), and olefinic (1649 cm^−1^) functionalities. The ^13^C NMR and DEPT data ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"}) of **1** exhibited 15 carbon resonances corresponding to four methyls, four methylenes, three methines, and four quaternary carbons (including one oxygenated, one olefinic, and two carbonyl). The olefinic carbons at *δ*~C~ 168.7 (C-7) and 127.1 (C-6) and the carbonyl carbon at *δ*~C~ 203.9 (C-5) showed characteristic chemical shifts for an *α*,*β*-unsaturated ketone ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"}). The presence of a 3-oxobutyl group was readily verified by ^1^H--^1^H COSY correlations of H-1/H~2~-2/H~2~-3 and HMBC correlations from H~3~-11 to C-3 and C-4 ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). Furthermore, ^1^H--^1^H correlation spectroscopy (^1^H--^1^H COSY) correlations of H~2~-8/H~2~-9/H-10/H-1 and heteronuclear multiple-bond correlation (HMBC) correlations from H-6 to C-1 and C-8, and from H~2~-9 to C-1 and C-7 suggested that compound **1** should possess a conjugated cycloheptenone core with a 3-oxobutyl side chain linked to C-1. Additionally, a doublet methyl at *δ*~H~ 0.80 (3H, H~3~-15) was connected to C-10 by ^1^H--^1^H COSY correlation of H-10/H~3~-15 and HMBC correlations from H~3~-15 to C-1, C-9, and C-10. Besides, signals of two downfield singlet methyls at *δ*~H~ 1.38 (6H, H~3~-13 and H~3~-14) and an additional oxygenated quaternary carbon at *δ*~C~ 74.0 (C-12), in combination with the molecular formula of **1**, indicated the presence of a 2-hydroxyprop-2-yl group, which was attached to C-7 by HMBC correlations from H~3~-13 and H~3~-14 to C-7, and from H-6 and H~2~-8 to C-12. Accordingly, compound **1** was thus elucidated as the 12-hydroxylated derivative of the co-isolated secoguaiane-type sesquiterpene **6** (gibberodione), which was previously isolated from a Formosan soft coral *S. gibberosa* \[[@B5-marinedrugs-16-00517]\].

The absolute configuration of **1** was determined to be the same as that of gibberodione, according to the nuclear overhauser effect spectroscopy (NOESY) experiment, comparison of corresponding chemical shifts and optical rotations with those reported analogs, and electronic circular dichroism (ECD) calculations. The *E*-geometry of the Δ^6(7)^-double bond was assigned by NOESY correlations of H-6/H~3~-13 and H-6/H~3~-14 ([Figure 3](#marinedrugs-16-00517-f003){ref-type="fig"}). NOESY correlations of H-1/H-10 and H~2~-2/H~3~-15 as well as the absence of H-1/H~3~-15 indicated the *cis*-orientation of H-1 and H-10, which was further supported by the chemical shifts of H~3~-15 at *δ*~H~ 0.80 and *δ*~C~ 16.3 recorded in CDCl~3~ (Ahmed et al. concluded that the chemical shifts of the secondary methyl at *δ*~H~ 0.83 and *δ*~C~ 15.7 in (1*S*, 10*S*) isomer were upfield, compared to *δ*~H~ 1.09 and *δ*~C~ 19.9 in (1*R*, 10*S*) isomer) \[[@B5-marinedrugs-16-00517]\]). The absolute configuration of **1** was determined by ECD calculations performed by the time dependent density functional theory (TDDFT)/ECD method \[[@B23-marinedrugs-16-00517]\]. The experimental ECD spectrum of **1**, which matched well with the calculated ECD spectrum for (1*S*, 10*S*) isomer, and showed mirror-image-like relationship with calculated ECD spectra for (1*R*, 10*R*) isomer ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}), proved the (1*S*, 10*S*) absolute configuration for **1**, corresponding to the same sign of optical rotation of **1** (\[*α*$\rbrack_{D}^{20}$ +10. 0, *c* 0.1, MeOH) as that of gibberodione (\[*α*$\rbrack_{D}^{20}$ +20.8, *c* 0.72, CHCl~3~).

*Epi*-gibberodione (**2**), afforded as a colorless oil, was assigned a molecular formula of C~15~H~24~O~2~ by (+)-HRESIMS ion at *m*/*z* 237.1852 \[M + H\]^+^ (calcd for C~15~H~25~O~2~, 237.1849) and ^13^C NMR data ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"}). 1D NMR ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}) together with ^1^H--^1^H COSY data of **2** revealed the presence of an *α*,*β*-unsaturated ketone, a 3-oxobutyl moiety, and an isopropyl group, implying compound **2** could be an analog of gibberodione \[[@B5-marinedrugs-16-00517]\]. That speculation was subsequently confirmed by detailed analyses of the ^1^H--^1^H COSY, heteronuclear singular quantum correlation (HSQC), and HMBC spectra, which established that compound **2** possessed an identical planar structure as gibberodione. NOESY correlations of H-6/H~3~-13 and H-6/H~3~-14 defined *E*-geometry of the Δ^6(7)^-double bond. Besides, NOESY correlations of H-1/H~3~-15 and the absence of H-1/H-10 indicated the *trans*-orientation of H-1 and H-10, which were confirmed by the chemical shift of H~3~-15 at *[δ]{.ul}*~H~ 1.10 recorded in CDCl~3~ (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}), because of the previous report that the *cis*-orientation isomer showed marked upfield shift for H~3~-15 relative to that of *trans*-orientation isomer and the upfield shift of H~3~-15 in gibberodione (*δ*~H~ 0.79) was detected \[[@B5-marinedrugs-16-00517]\]. The overall pattern of experimental ECD spectrum of compound **2** exhibiting positive Cotton effect at 241 nm and negative Cotton effect at 320 nm matched well with the (1*R*, 10*S*) isomer and mirrored with (1*S*, 10*R*) isomer in the calculated ECD spectra ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}), permitting assignment of the (1*R*, 10*S*) absolute configuration for compound **2**.

Molestin B (**3**) was obtained as a colorless oil having a molecular formula of C~15~H~24~O~2~ as deduced from the protonated molecular \[M + H\]^+^ at *m*/*z* 237.1853 (calcd for C~15~H~25~O~2~, 237.1849) in the (+)-HRESIMS spectrum and ^13^C NMR data ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"}). The ^13^C NMR and DEPT spectra showed 15 carbon signals, which were assigned as four methyls, four methylenes, three methines, and four quaternary carbons (including two olefinic, one oxygenated, and one conjugated carbonyl). Additionally, the characteristic carbon resonances at *δ*~C~ 174.0 (C-5), 138.6 (C-4), and 208.7 (C-3) attributed to an *α*,*β*-unsaturated ketone group were also observed. Considering all these data as well as four degrees of unsaturation, compound **3** was predicted to be a bicyclic sesquiterpene. The presence of an isopropyl group was verified by the ^1^H--^1^H COSY correlations of H~3~-13/H-12/H~3~-14 ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). The aforementioned information together with the sequential ^1^H--^1^H COSY correlations of H~2~-8/H~2~-9/H-10/H-1/H~2~-2 implied that the structure of **3** was analogous to the guaiane-type sesquiterpene torilolone \[[@B24-marinedrugs-16-00517]\]. The HMBC correlations from H~3~-11 to C-3, C-4, and C-5; from H~3~-13 and H~3~-14 to C-7; from H~3~-15 to C-1, C-9, and C-10; from H~2~-2 to C-1, C-3, C-5, and C-10; and from H~2~-6 to C-4, C-5, C-7, and C-8 further constructed the planar structure of compound **3** ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). The NOESY correlations of H-10/H~3~-13 suggested the cofacial arrangement of H~3~-15 and 7-OH. In addition, the *cis*-disposition of H-1 and H-10 was deduced from chemical shift of H-10 (*δ*~H~ 2.08) and H~3~-15 (*δ*~H~ 0.65) in ^1^H NMR spectrum recorded in CDCl~3~ \[[@B5-marinedrugs-16-00517],[@B25-marinedrugs-16-00517]\]. The overall pattern of experimental ECD spectrum of compound **3** matched well with the calculated ECD curve for (1*S*, 7*R*, 10*S*) isomer ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}), demonstrating the (1*S*, 7*R*, 10*S*) absolute configuration for compound **3**.

Molestin C (**4**), a yellow oil, had a molecular formula of C~15~H~22~O~2~ based on its (+)-HRESIMS ion at *m*/*z* 235.1693 \[M + H\]^+^ (calcd for C~15~H~23~O~2~, 235.1693), requiring five degrees of unsaturation. Compound **4** shared a similar guaiane-type sesquiterpene skeleton with compound **3** by comparison of their 1D NMR data ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}). The spin-spin coupling system of H~2~-8/H~2~-9/H-10/H~3~-15 and H~3~-13/H-12/H~3~-14 deduced from ^1^H--^1^H COSY spectrum and HMBC correlations from H~3~-11 to C-3, C-4 and C-5; from H-12 to C-6 and C-8; from H~3~-15 to C-1, C-9 and C-10; from H~2~-3 to C-1 and C-5; from H-6 to C-1, C-4, and C-8; and from H-10 to C-2 and C-5 ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}) completed the planner structure assignment as depicted for compound **4**. The *E*-geometry of the Δ^6(7)^-double bond was verified by NOESY correlations of H-6/H~3~-13 and H-6/H~3~-14. To determine the absolute configuration of compound **4**, ECD spectra of the four configurational isomers were calculated. Results revealed that the experimental ECD spectrum of compound **4** was consistent with the calculated ECD spectrum for (4*R*, 10*R*) configuration only ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}). Accordingly, the (4*R*, 10*R*) absolute configuration was assigned for compound **4**.

Molestin D (**5**) was isolated as a yellow oil, with a molecular formula of C~13~H~20~O~3~ based on (+)-HRESIMS ion at *m*/*z* 242.1753 \[M + NH~4~\]^+^ (calcd for C~13~H~24~O~3~N, 242.1751) and ^13^C NMR data ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"}), implying four degrees of unsaturation. Typical resonances at *δ*~C~162.7 (C-5), 127.1 (C-6), and 205.3 (C-7) in ^13^C NMR spectrum indicated the presence of an *α*,*β*-unsaturated ketone group. The comparisons of 1D NMR spectroscopic data of compound **5** with those of **1**--**4** ([Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}) indicated that compound **5** was likely to be a de-isopropyl guaiane-type sesquiterpene. That speculation was confirmed by ^1^H--^1^H COSY correlations of H~2~-8/H~2~-9/H-10/H~3~-12 and HMBC correlations from H~2~-2 to C-4, C-5, and C-10; from H-6 to C-1, C-4, and C-8; from H~3~-11 to C-3, C-4, and C-5; and from H~3~-12 to C-1, C-9, and C-10 ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). Additionally, HMBC correlation from 1-OCH~3~ to C-1 demonstrated the location of the methoxyl at C-1 in compound **5**. NOESY correlation of H-6/H~3~-11 suggested *E*-geometry of the Δ^5^-double bond ([Figure 3](#marinedrugs-16-00517-f003){ref-type="fig"}). Besides, NOESY correlations of 1-OCH~3~/H-10 and 1-OMe/H~3~-11, along with the absence of 1-OCH~3~/H~3~-12 suggested that 1-OCH~3~, H-10, and H~3~-11 were on the same side of the ring system. On the other hand, the *cis*-oritation of 1-OCH~3~ and H-10 was indicated by the chemical shift of H-10 (*δ*~H~ 2.30) in compound **5**, because it was reported that the chemical shifts for *trans*-oritation of 1-OH and H-10 in its analogs are more upfield \[[@B26-marinedrugs-16-00517],[@B27-marinedrugs-16-00517]\]. The (1*R*, 4*S*, 10*S*) absolute configuration for molestin D (**5**) was identified through ECD calculations, in which the experimental ECD spectrum of compound **5** showed good agreement with the calculated ECD spectrum for (1*R*, 4*S*, 10*S*) configuration ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}).

*ent*-sinulolide C ((+)-**9**), a colorless oil, was deduced to have a molecular formula of C~15~H~24~O~4~ according to the (+)-HRESIMS ions at *m*/*z* 269.1747 \[M + H\]^+^ (calcd for C~15~H~25~O~4~, 269.1747) and *m*/*z* 291.1565 \[M + Na\]^+^ (calcd for C~15~H~24~O~4~Na, 291.1567). The ^1^H NMR spectrum (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}) exhibited one methoxyl at *δ*~H~ 3.77 (3H, s, 7-OCH~3~), two olefinic singlet methyls at *δ*~H~ 2.02 (3H, s, H~3~-14) and 1.73 (3H, s, H~3~-13), and one terminal triplet methyl at *δ*~H~ 0.83 (3H, t, *J* = 6.7 Hz, H~3~-12). The characteristic carbon signals at *δ*~C~ 168.8 (C-3), 135.7 (C-2), and 202.9 (C-1) in ^13^C NMR spectrum (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}) indicated the presence of an *α*,*β*-unsaturated ketone group in compound **9**. Besides, the consecutive correlations of H~2~-8/H~2~-9/H~2~-10/H~2~-11/H~3~-12 observed in ^1^H--^1^H COSY spectrum formed a pentane linear side chain in **9** ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). The aforementioned data bear remarkable similarities to those of sinulolide C \[[@B11-marinedrugs-16-00517]\]. In addition, further comparative analyses of 1D and 2D NMR data of compound **9** and sinulolide C suggested that the two compounds shared an identical planner structure. NOESY correlation of H-6b (*δ*~H~ 2.38)/H-8b (*δ*~H~ 1.53) in compound **9** clarified the same relative configuration as sinulolide C. However, just as the natural occurring analogs (±)-foedanolide ((±)-**12**) \[[@B28-marinedrugs-16-00517]\], compound **9** was optically inactive, indicating **9** to be a racemate. The chiral HPLC separation of **9** yielded optical pure compounds (+)-**9** and (−)-**9** (sinulolide C), with a ratio of approximately 1:1 ([Figure S79, Supplementary Materials](#app1-marinedrugs-16-00517){ref-type="app"}). The opposite optical rotations of respective +17.8 (*c* 0.05, MeOH) and −23.5 (*c* 0.05, MeOH), as well as mirror-image-like experimental ECD curves ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}) of compounds (+)-**9** and (−)-**9**, suggested the (4*S*, 5*S*) absolute configuration for *ent*-sinulolide C ((+)-**9**), by comparison with those of sinulolide C, sinularone B \[[@B12-marinedrugs-16-00517]\], and (±)-sinularone J \[[@B8-marinedrugs-16-00517]\].

*ent*-sinulolide D ((+)-**10**) was obtained as a colorless oil. Its molecular formula of C~14~H~22~O~4~ was determined by the (−)-HRESIMS ion at *m*/*z* 253.1440 \[M − H\]^−^ (calcd for C~14~H~21~O~4~, 253.1445). The 1D NMR data of **10** (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}) revealed that its structural features were very close to those of **9**, differing only in the absence of a methoxyl at C-7 in **10**. The planar structure of compound **10** was unambiguously proved to be the same with sinulolide D by ^1^H--^1^H COSY and HMBC correlations \[[@B11-marinedrugs-16-00517]\]. Moreover, NOESY correlation of H-6b (*δ*~H~ 2.64)/H-8b (*δ*~H~ 1.79) in compound **10** disclosed the same relative configuration as sinulolide D. Similarly, Compound **10** was initially isolated as a racemic mixture, and was separated by chiral HPLC to afford (+)-**10** (\[*α*$\rbrack_{D}^{20}$ +44.6, *c* 0.2, MeOH) and (--)-**10** (sinulolide D, \[*α*$\rbrack_{D}^{20}$ −42.1, *c* 0.2, MeOH) with a ratio of 1:1 ([Figure S80, Supplementary Materials](#app1-marinedrugs-16-00517){ref-type="app"}). Comparing the optical rotations as well as experimental ECD spectra of compounds (+)-**10** and (−)-**10** ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}) with those of analogs \[[@B8-marinedrugs-16-00517],[@B11-marinedrugs-16-00517],[@B12-marinedrugs-16-00517]\], the absolute configuration for *ent*-sinulolide D ((+)-**10**) was clearly assigned as (4*S*, 5*S*). The co-occurrence of compounds **9** and **10** in the extract and the fact that MeOH was used during the extraction process suggested that compound **9** is likely a 7-*O*-methyl artifact of **10**.

*ent*-sinulolide F ((+)-**11**), obtained as a colorless oil, was defined a molecular formula of C~15~H~24~O~5~ by the (+)-HRESIMS ion at *m*/*z* 307.1511 \[M + Na\]^+^ (calcd for C~15~H~24~O~5~Na, 307.1516). The 1D NMR spectroscopic data of compound **11** (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}) were very close to those of compound **9**, except for the presence of a methoxyl (*δ*~H~ 3.39, *δ*~C~ 60.4) and an oxygenated methane (*δ*~H~ 3.60, *δ*~C~ 80.9), instead of one methylene (*δ*~H~ 1.77 and 1.53, *δ*~C~ 37.1) in **9**. The ^1^H--^1^H COSY and HMBC data finally defined the planner structure of compound **11**, which was identical to sinulolide F \[[@B11-marinedrugs-16-00517]\]. The relative configuration of **11** was shown to be the same as that of sinulolide F based on equivalent NMR data and NOESY correlation of H-6a (*δ*~H~ 3.06)/H-8 (*δ*~H~ 3.60). Compound **11** was also separated by chiral HPLC to obtain (+)-**11** and (--)-**11** (sinulolide F), with an enantiomeric ratio of 1:1 ([Figure S81, Supplementary Materials](#app1-marinedrugs-16-00517){ref-type="app"}). Comparison of the experimental ECD spectra for compounds (±)-**11** ([Figure 4](#marinedrugs-16-00517-f004){ref-type="fig"}) and sinulolide F suggested the (4*S*, 5*S*) configuration for *ent*-sinulolide F ((+)-**11**). However, the configurations at C-8 in compounds (±)-**11** were still undetermined.

*ent*-sinulolide H ((+)-**13**), a colorless oil, had a molecular formula of C~11~H~16~O~5~ based on the (+)-HRESIMS ion at *m*/*z* 251.0895 \[M + Na\]^+^ (calcd for C~11~H~16~O~5~Na, 251.0890), implying four degrees of unsaturation. In the ^13^C NMR spectrum, three quaternary signals at *δ*~C~ 155.9 (C-3), 127.8 (C-2), and 171.4 (C-1) attributed to an *α*,*β*-unsaturated ester group were exhibited (see [Section 3.3](#sec3dot3-marinedrugs-16-00517){ref-type="sec"}). The ^1^H NMR data showed two downfield singlet methyls at *δ*~H~ 1.88 (3H, s, H~3~-9) and 1.85 (3H, s, H~3~-8), which were attached to C-2 and C-3 by HMBC correlations from H~3~-8 to C-1 and C-3, and from H~3~-9 to C-2 and C-4, respectively. The presence of a methyl propionate fragment was confirmed by the ^1^H--^1^H COSY correlation of H~2~-5/H~2~-6 and HMBC correlations from H~2~-5 and 7-OCH~3~ to C-7 ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). In addition, resonances of one notable downfield quaternary carbon at *δ*~C~ 109.0 (C-4) as well as a methoxyl at *δ*~C~ 50.4 (4-OCH~3~) were observed in the ^13^C NMR spectrum. The above information strongly indicated that compound **13** was likely to have the same planner structure as the 2,3-dimethyl butenolide derivative sinulolide H \[[@B11-marinedrugs-16-00517]\], which was then confirmed by ^1^H--^1^H COSY and HMBC correlations ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). Compound **13** was further purified by chiral HPLC chromatography to obtain (+)-**13** (\[*α*$\rbrack_{D}^{20}$ +8.6, *c* 0.01, MeOH) and (--)-**13** (sinulolide H, \[*α*$\rbrack_{D}^{20}$ --10.3, *c* 0.01, MeOH) ([Figure S83, Supplementary Materials](#app1-marinedrugs-16-00517){ref-type="app"}). The absolute configuration of *ent*-sinulolide H ((+)-**13**) was determined as 4*S* by comparing the optical rotations with those of the analogs sinulolide H (\[*α*$\rbrack_{D}^{20}$ --3.2, *c* 0.03, MeOH) and sinularone H (\[*α*$\rbrack_{D}^{20}$ +3.7, *c* 0.12, MeOH) \[[@B12-marinedrugs-16-00517]\].

Molestin E (**14**) was isolated as a yellow oil and had a molecular formula of C~23~H~28~O~9~ as determined by (+)-HRESIMS ion at *m*/*z* 466.2063 \[M + NH~4~\]^+^ (calcd for C~23~H~32~O~9~N, 466.2072). Absorption for hydroxy and carbonyl groups at 3370, 1751, and 1698 cm^--1^ were observed in the IR spectrum. The 1D NMR data of compound **14** ([Table 3](#marinedrugs-16-00517-t003){ref-type="table"}) were similar to those of the co-occurring compounds **15** and **16**. ^1^H NMR spectrum of **14** displayed signals at *δ*~H~ 6.75 (1H, s, H-5), 6.10 (1H, s, H-11), and 4.81 (2H, d, *J* = 6.1 Hz, H~2~-16) ascribed to a trisubstituted furan, a disubstituted butyrolactone ring, and a terminal olefin, respectively, as found in sinulacembranolide A isolated from the soft coral *S. gaweli* \[[@B29-marinedrugs-16-00517]\]. The ^13^C NMR and DEPT spectra of **14** showed the presence of 23 carbon signals which were assigned to four methyls, four methylenes (including one terminal olefinic), six methines (including two oxygenated, two olefinic), and nine quaternary carbons (including one oxygenated, four olefinic, and three carbonyl), indicating compound **14** could be the deacetyl analog of sinulacembranolide A. Connectivity information obtained from 2D NMR, especially ^1^H--^1^H COSY and HMBC experiments, unambiguously confirmed the above speculation, and determined the planar structure of **14** ([Figure 2](#marinedrugs-16-00517-f002){ref-type="fig"}). The relative configuration of **14** was elucidated by NOESY spectrum. NOESY correlation of H-1/H-13 suggested that H-1 and H-13 were on the same side of the ring system. NOESY correlations of H-1/H-2*α* (*δ*~H~ 2.75) and H-7/H-2*α* assigned the *α*-orientation of H-1, H-7, and H-13 ([Figure 3](#marinedrugs-16-00517-f003){ref-type="fig"}). The same side of H~3~-19 and H-10 were determined based on NOESY correlations of H~3~-19/H-10, and their *β*-orientation were finally defined by NOESY correlations of H~3~-19/H-9*β* (*δ*~H~ 2.60), H-10/H-9*β*, H-7/H-9*α* (*δ*~H~ 1.80), and H-13/H-9*α*. That allowed the assignment of the relative configuration of **14** as (1*S*\*, 7*R*\*, 8*S*\*, 10*R*\*, 13*R*\*).

The known compounds, including three sesquiterpenes (**6**--**8**), five cyclopentenone derivatives ((--)-**9**--(--)-**11**, and (±)-**12**), one butenolide derivative ((--)-**13**), and five diterpenes (**15**--**19**) were identified as gibberodione \[[@B5-marinedrugs-16-00517]\], polydactin A \[[@B30-marinedrugs-16-00517]\], (5′*Z*)-5-(2′,6′-Dimethylocta-5′,7′-dienyl)-furan-3- carboxylic acid \[[@B31-marinedrugs-16-00517]\], sinulolide C \[[@B11-marinedrugs-16-00517]\], sinulolide D \[[@B11-marinedrugs-16-00517]\], sinulolide F \[[@B11-marinedrugs-16-00517]\], (±)-foedanolide ((±)-sinularone D) \[[@B12-marinedrugs-16-00517],[@B28-marinedrugs-16-00517]\], sinulolide H \[[@B11-marinedrugs-16-00517]\], leptodiol \[[@B32-marinedrugs-16-00517]\], (--)-leptodiol acetate \[[@B29-marinedrugs-16-00517]\], 5-*epi*-sinuleptolide \[[@B33-marinedrugs-16-00517]\], sinuleptolide \[[@B34-marinedrugs-16-00517],[@B35-marinedrugs-16-00517]\], and scabrolide A \[[@B36-marinedrugs-16-00517]\], by comparing their spectroscopic data with those reported earlier.

Considering the reported cytotoxic activities of some sesquiterpenes \[[@B30-marinedrugs-16-00517]\], cyclopentenone derivatives \[[@B28-marinedrugs-16-00517]\], and cembranoid diterpenes \[[@B36-marinedrugs-16-00517]\], all the compounds were evaluated for their cytotoxic activities against HeLa (human cervical carcinoma), HCT-116 (human colon carcinoma), BEL-7402 (human hepatocellular carcinoma), K562 (human leukemia), and Jurkat (human acute leukemia T) tumor cell lines. Only three cembranoid diterpenes showed valuable cytotoxicities against the selected cell lines (IC~50~ \< 10 μM). Molestin E (**14**) exhibited cytotoxicities against HeLa and HCT-116 cell lines with IC~50~ values of 5.26 and 8.37 μM, respectively. Compounds **17** and **18** showed cytotoxicities against HeLa cell lines with IC~50~ values of 6.66 and 6.10 μM, respectively.

Considering some guaiane-type sesquiterpenes and furanoterpenoids previously reported showed inhibitory activities against protein tyrosine phosphatase 1B (PTP1B) \[[@B37-marinedrugs-16-00517],[@B38-marinedrugs-16-00517],[@B39-marinedrugs-16-00517]\], a major negative regulator in insulin signaling pathways \[[@B40-marinedrugs-16-00517]\]. Inhibiting PTP1B activity could increase insulin sensitivity and is expected to be a potential promising therapeutic for type 2 diabetes and obesity \[[@B41-marinedrugs-16-00517]\]. These isolated sesquiterpenes were also assessed for their inhibitory activities against PTP1B. In addition, the results revealed that two guaiane-type sesquiterpenes (**4** and **5**) and a furanosesquiterpene (**8**) displayed strong inhibitory activities against PTP1B with IC~50~ values of 218, 344, and 1.24 μM, respectively, lower than the positive control (the IC~50~ value of sodium orthovanadate was 881 μM).

3. Materials and Methods {#sec3-marinedrugs-16-00517}
========================

3.1. General Methods {#sec3dot1-marinedrugs-16-00517}
--------------------

Optical rotations were measured on a JASCO P-1020 digital polarimeter. Ultra-violet (UV) spectra were measured on a Beckman DU640 spectrophotometer. ECD spectra were obtained on a JASCO J-810 spectropolarimeter. IR spectra were recorded on a Nicolet Nexus 470 FT-IR spectrophotometer in KBr discs. 1D and 2D NMR spectra were recorded on a JEOL JNMECP 500 spectrometer (500 MHz for ^1^H and 125 MHz for ^13^C) using tetramethylsilane as an internal standard. Chemical shifts are expressed in *δ* (ppm) referring to the solvent peaks at *δ*~H~ 7.26 and *δ*~C~ 77.16 for CDCl~3~, and *δ*~H~ 3.31 and *δ*~C~ 49.50 for methanol-*d*~4~ and coupling constant *J* in Hz. HRESIMS data were acquired on a Thermo Scientific LTQ Orbitrap XL mass spectrometer or a Micromass Q-Tof Ultima GLOBAL GAA076 mass spectrometer, equipped with an electrospray ionization (ESI) source, and the ionization mode was positive or negative. Semipreparative HPLC separations were carried out using an Agilent 1100 series instrument with a diode array detector (DAD) detector, equipped with a reversed-phase column (YMC-Pack ODS-A, 5 μm, 250 × 10 mm). Chiral HPLC analysis and resolution were conducted on a chiral analytical column (Daicel Chiralpack IC, 5 μm, 250 × 4.6 mm). Silica gel (200--300 mesh, 300--400 mesh; Qingdao Marine Chemical Co. Ltd., Qingdao, China), ODS silica gel (50 μm, Merck, Darmstadt, Germany) and Sephadex LH-20 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) were used to perform column chromatography (CC). Precoated silica gel plates (GF254, Qingdao Marine Chemical Co. Ltd., Qingdao, China) were used for thin layer chromatography (TLC) analyses, and spots were visualized under UV light and by spraying with 10% H~2~SO~4~ in EtOH.

3.2. Animal Material {#sec3dot2-marinedrugs-16-00517}
--------------------

The soft coral *S.* cf. *molesta* was collected from the Paracel Islands of the South China Sea in October 2012, at a depth of about 10 m, and was frozen immediately until it was examined. The specimen was identified by Dr. Leen van Ofwegen, a co-author of this paper.. A voucher specimen (NO. XS-2012-22) was deposited in the school of Medicine and Pharmacy, Ocean University of China, China.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00517}
-----------------------------

The frozen organism (5.0 kg, wet weight; 2.2 kg, dry weight) was homogenized and extracted with MeOH four times (each time, 5 L, 3 d) at room temperature. The combined solutions were concentrated in vacuum and desalted by anhydrous MeOH three times (0.6 L, 0.5 L, 0.4 L) to yield a residue (95.0 g). The crude extract was subjected to silica gel vacuum liquid chromatography (VLC), eluting with a gradient of petroleum ether (PE)/acetone (150:1--1:1) and subsequently CH~2~Cl~2~/MeOH (20:1--1:1) to obtain seven fractions (Frs. 1--7). Fr. 2 was subjected to silica gel CC using PE/acetone (100:1--5:1 gradient) as eluent to give four subfractions (Frs. 2.1--2.4). Fr. 2.2 was separated by ODS CC (MeOH/H~2~O, 60:40−100:0 gradient) to yield four subfractions (Frs. 2.2.1--2.2.4). Fr. 2.2.2 was further purified by semipreparative HPLC (ODS; MeOH/H~2~O, 60:40) to afford compounds 1 (3.5 mg) and 2 (1.7 mg). Fr. 2.2.3 was purified by semipreparative HPLC (ODS; MeOH/H~2~O, 40:60) to afford compounds 6 (10.0 mg) and 7 (2.1 mg). Fr. 3 was applied to silica gel CC (PE/acetone, 50:1--1:1 gradient) to yield six subfractions (Frs. 3.1--3.6). Fr. 3.3 was further separated by CC (Sephadex LH-20; CHCl~3~/MeOH, 1:1), and then semipreparative HPLC (ODS; MeOH/H~2~O, 40:60) to afford compound 13 (2.5 mg). Fr. 3.5 was purified by ODS CC (MeOH/H~2~O, 40:60−80:20 gradient) and then semipreparative HPLC (ODS; MeOH/H~2~O, 40:60) to yield compounds 3 (32.0 mg), 4 (2.1 mg), and 5 (2.5 mg). Fr. 4 was fractionated into six subfractions (Fr. 4.1−4.6) by silica gel CC (PE/acetone, 40:1--1:1 gradient). Fr. 4.2 was fractionated by ODS CC, eluted with MeOH/H~2~O (30:70−80:20 gradient), followed by semipreparative HPLC (MeOH/H~2~O, 55:45), to afford compounds 10 (5.0 mg) and 12 (18.0 mg). Repeated Sephadex LH-20 CC (CHCl~3~/MeOH, 1:1), followed by ODS CC (MeOH/H~2~O, 30:70−80:20 gradient) and then semipreparative HPLC (MeOH/H~2~O, 45:55), gave compounds 14 (14.0 mg), 15 (33.0 mg), 16 (1.8 mg), 17 (55.0 mg), 18 (43.0 mg), and 19 (1.5 mg) from Fr. 4.5. Fr. 5 was separated by silica gel CC (PE/acetone, 20:1−1:1 gradient) to provide five subfractions (Fr. 5.1−5.5). Fr. 5.5 was separated by Sephadex LH-20 CC (CH~2~Cl~2~/MeOH, 1:1), followed by semipreparative HPLC (MeOH/H~2~O, 55:45), to yield compounds 8 (4.5 mg), 9 (1.6 mg), and 11 (1.5 mg). Chiral separations of (±)-9−(±)-13 (chiral HPLC column; *n*-hexane/*i*-PrOH 80:20, 90:10, 70:30, 97:3, and 85:15, respectively) to resolved into optically pure compounds (+)-9 (0.8 mg), (--)-9 (0.8 mg), (+)-10 (2.1 mg), (−)-10 (2.2 mg), (+)-11 (0.7 mg), (−)-11 (0.7 mg), (+)-12 (8.7 mg), (−)-12 (8.8 mg), (+)-13 (1.2 mg), and (−)-13 (1.2 mg). During the HPLC separations, the injection volume was less than 40 μL (semipreparative HPLC) or 5 μL (chiral HPLC) and the column temperature was maintained at about 30 °C.

*Molestin A* (**1**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +10.0 (*c* 0.1, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 241 (−9.1), 328 (3.9) nm; IR (KBr) *ν*~max~ 3151, 2975, 2932, 2872, 1712, 1649,1453, 1379, 1217, 1096 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}; HRESIMS *m*/*z* 253.1803 \[M + H\]^+^ (calcd for C~15~H~25~O~3~, 253.1798).

*Epi-gibberodione* (**2**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +9.8 (*c* 0.1, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 242 (10.1), 320 (−5.2) nm; IR (KBr) *ν*~max~ 2954, 2803, 1703, 1652, 1465, 1382, 1190 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~) *δ* 5.84 (1H, br d, *J* = 2.1 Hz, H-6), 2.11 (3H, s, H~3~-11), 1.10 (3H, d, *J* = 6.2 Hz, H~3~-15), 1.07 (3H, d, *J* = 6.6 Hz, H~3~-13), 1.06 (3H, d, *J* = 6.8 Hz, H~3~-14). ^1^H and ^13^C NMR data (methanol-*d*~4~), see [Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}; HRESIMS *m*/*z* 237.1852 \[M + H\]^+^ (calcd for C~15~H~25~O~2~, 237.1849).

*Molestin B* (**3**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +37.9 (*c* 0.1, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 242 (9.9), 316 (−1.4) nm; IR (KBr) *ν*~max~ 3451, 2972, 2850, 1685, 1496, 1383, 1167, 996 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}; HRESIMS *m*/*z* 237.1853 \[M + H\]^+^ (calcd for C~15~H~25~O~2~, 237.1849).

*Molestin C* (**4**): yellow oil; \[*α*$\rbrack_{D}^{20}$ +110.9 (*c* 0.1, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 213 (−0.2), 229 (3.3), 298 (5.6), 337 (−10.3) nm; IR (KBr) *ν*~max~ 3450, 2961, 2780, 1683,1506, 1381, 1257,1035 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}; HRESIMS *m*/*z* 235.1693 \[M + H\]^+^ (calcd for C~15~H~23~O~2~, 235.1693).

*Molestin D* (**5**): yellow oil; \[*α*$\rbrack_{D}^{20}$ +39.4 (*c* 0.2, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 212 (22.8), 238 (−44.2), 322 (10.9) nm; IR (KBr) *ν*~max~ 3417, 2966, 1666, 1458, 1052, 916, 870 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-16-00517-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00517-t002){ref-type="table"}; HRESIMS *m*/*z* 242.1753 \[M + NH~4~\]^+^ (calcd for C~13~H~24~O~3~N, 242.1751).

*ent-sinulolide C* ((+)**-9**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +17.8 (*c* 0.05, MeOH); ECD (MeOH) *λ*~max~ (Δ*ε*) 210 (40.9), 236 (−79.5), 314 (22.1) nm; UV (MeOH) *λ*~max~ (log *ε*) 224 (2.16) nm; IR (KBr) *ν*~max~ 3445, 2985, 2921, 1730, 1643, 1457, 1370, 1163 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~) *δ* 2.85 (1H, dd, *J* = 11.7, 2.9 Hz, H-5), 3.15 (1H, dd, *J* = 18.5, 3.2 Hz, H-6a), 2.38 (1H, dd, *J* = 18.6, 11.8 Hz, H-6b), 1.77 (1H, td, *J* = 13.5, 5.3 Hz, H-8a), 1.53 (1H, td, *J* = 12.1, 3.8 Hz, H-8b), 0.76 (1H, m, H-9a), 0.64 (1H, m, H-9b), 1.20 (4H, m, H~2~-10, H~2~-11), 0.83 (3H, t, *J* = 6.7 Hz, H~3~-12), 1.73 (3H, s, H~3~-13), 2.02 (3H, s, H~3~-14), 3.77 (3H, s, 7-OCH~3~); ^13^C NMR (125 MHz, CDCl~3~) *δ* 202.9 (C, C-1), 135.7 (C, C-2), 168.8 (C, C-3), 80.6 (C, C-4), 55.2 (CH, C-5), 30.0 (CH~2~, C-6), 175.4 (C, C-7), 37.1 (CH~2~, C-8), 25.2 (CH~2~, C-9), 32.1 (CH~2~, C-10), 22.5 (CH~2~, C-11), 14.1 (CH~3~, C-12), 8.0 (CH~3~, C-13), 11.7 (CH~3~, C-14), 52.6 (CH~3~, 7-OCH~3~); HRESIMS *m*/*z* 269.1747 \[M + H\]^+^ (calcd for C~15~H~25~O~4~, 269.1747), *m*/*z* 291.1565 \[M + Na\]^+^ (calcd for C~15~H~24~O~4~Na, 291.1567).

*ent-sinulolide D* ((+)-**10**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +44.6 (*c* 0.2, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 228 (2.60) nm; ECD (MeOH) *λ*~max~ (Δ*ε*) 229 (−89.1), 320 (9.0) nm; IR (KBr) *ν*~max~ 3422, 2959, 2860, 1735, 1610, 1469, 1365, 1103 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~) *δ* 2.94 (1H, overlap, H-5), 2.96 (1H, overlap, H-6a), 2.64 (1H, d, *J* = 15.5 Hz, H-6b), 2.01 (1H, td, *J* = 14.4, 4.2 Hz, H-8a), 1.79 (1H, m, H-8b), 135−1.25 (5H, m, H-9a, H~2~-10, and H~2~-11), 1.11 (1H, m, H-9b), 0.89 (3H, t, *J* = 6.8 Hz, H~3~-12), 1.76 (3H, s, H~3~-13), 2.07 (3H, s, H~3~-14); ^13^C NMR (125 MHz, CDCl~3~) *δ* 204.7 (C, C-1), 139.2 (C, C-2), 167.2 (C, C-3), 92.4 (C, C-4), 46.7 (CH, C-5), 32.6 (CH~2~, C-6), 174.5 (C, C-7), 34.7 (CH~2~, C-8), 23.4 (CH~2~, C-9), 31.9 (CH~2~, C-10), 22.6 (CH~2~, C-11), 14.1 (CH~3~, C-12), 8.3 (CH~3~, C-13), 12.4 (CH~3~, C-14); HRESIMS *m*/*z* 253.1440 \[M − H\]^+^ (calcd for C~14~H~21~O~4~, 253.1445).

*ent-sinulolide F* ((+)-**11**): colorless oil; \[*α*$\rbrack_{D}^{20}$ +9.8 (*c* 0.04, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 229 (2.93) nm; ECD (MeOH) *λ*~max~ (Δ*ε*) 208 (90.9), 226 (−28.5), 246 (26.9) nm; IR (KBr) *ν*~max~ 3385, 2927, 1722, 1635, 1480, 1377, 1145 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~) *δ* 2.91 (1H, dd, *J* = 19.1, 12.5 Hz, H-5), 3.06 (1H, dd, *J* = 12.5, 4.6 Hz, H-6a), 2.59 (1H, dd, *J* = 19.1, 4.6 Hz, H-6b), 3.60 (1H, dd, *J* = 8.8, 2.9 Hz, H-8), 1.52 (1H, m, H-9a), 1.34 (5H, m, H-9b, H~2~-10, H~2~-11), 0.92 (3H, t, *J* = 7.1 Hz, H~3~-12), 1.78 (3H, s, H~3~-13), 2.13 (3H, s, H~3~-14), 3.39 (3H, s, 8-OCH~3~); ^13^C NMR (500 MHz, CDCl~3~) *δ* 204.6 (C, C-1), 140.1 (C, C-2), 165.8 (C, C-3), 93.0 (C, C-4), 44.2 (CH, C-5), 32.3 (CH~2~, C-6), 174.4 (C, C-7), 80.9 (CH, C-8), 30.7 (CH~2~, C-9), 28.8 (CH~2~, C-10), 23.0 (CH~2~, C-11), 14.2 (CH~3~, C-12), 8.5 (CH~3~, C-13), 13.2 (CH~3~, C-14), 60.4 (CH~3~, 8-OCH~3~); HRESIMS *m*/*z* 307.1511 \[M + Na\]^+^ (calcd for C~15~H~24~O~5~Na, 307.1516).

*ent-sinulolide H* ((+)-**13**): colorless oil, \[*α*$\rbrack_{D}^{20}$ +8.6 (*c* 0.01, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 233 (2.10) nm; IR (KBr) *ν*~max~ 2815, 2700, 1750, 1485, 1311, 1084 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~) *δ* 2.52 (1H, m, H-5a), 2.38 (1H, m, H-5b), 2.30 (1H, m, H-6a), 1.96 (1H, m, H-6b), 1.85 (3H, s, H~3~-8), 1.88 (3H, s, H~3~-9), 3.08 (3H, s, 4-OCH~3~), 3.66 (3H, s, 7-OCH~3~); ^13^C NMR (125 MHz, CDCl~3~) *δ* 171.4 (C, C-1), 127.8 (C, C-2), 155.9 (C, C-3), 109.0 (C, C-4), 28.0 (CH~2~, C-5), 31.4 (CH~2~, C-6), 173.4 (C, C-7), 8.6 (CH~3~, C-8), 10.9 (CH~3~, C-9), 50.4 (CH~3~, 4-OCH~3~), 51.9 (CH~3~, 7-OCH~3~); HRESIMS *m*/*z* 251.0895 \[M + Na\]^+^ (calcd for C~11~H~16~O~5~Na, 251.0890).

*Molestin E* (**14**): yellow oil; \[*α*$\rbrack_{D}^{20}$ +13.2 (*c* 0.2, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 264 (2.96) nm; IR (KBr) *ν*~max~ 3481, 1756, 1721, 1580, 1396, 1185 cm^−1^; ^1^H and ^13^C NMR data, see [Table 3](#marinedrugs-16-00517-t003){ref-type="table"}; HRESIMS *m*/*z* 466.2063 \[M + NH~4~\]^+^ (calcd for C~23~H~32~O~9~N, 466.2072).

3.4. ECD Calculations of Compounds ***1**--**5*** {#sec3dot4-marinedrugs-16-00517}
-------------------------------------------------

The quantum chemical calculations were performed by using the density functional theory (DFT) as implemented in Gaussian 09 \[[@B42-marinedrugs-16-00517]\]. The initial structures of compounds 1--5 were built with Spartan 10 software and all trial structures were first minimized based on molecular mechanics calculations. Conformational searches were performed by Spartan 10 software using Merck Molecular Force Field (MMFF), and conformers occurring within a 10 kcal/mol energy window from the global minimum were chosen for geometry optimization in the gas phase with the DFT method at the B3LYP/6-31G (d,p) level. The stable conformations of 1--5 were calculated for ECD spectra using TD-DFT method with the basis set RB3LYP/ DGDZVP \[[@B23-marinedrugs-16-00517]\]. Solvent effects of MeOH were evaluated at the same DFT level by using the SCRF/PCM method. The ECD spectra were combined after Boltzmann weighting according to their population contribution ([Figure S84--S88, Supplementary Materials](#app1-marinedrugs-16-00517){ref-type="app"}).

3.5. Cytotoxicity Assay {#sec3dot5-marinedrugs-16-00517}
-----------------------

In vitro cytotoxicities were determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*- tetrazolium bromide) colorimetric method \[[@B43-marinedrugs-16-00517]\] against K562 and Jurkat cell lines, and SRB (Sulforhodamine B) method \[[@B44-marinedrugs-16-00517]\] against HeLa, HCT-116, and BEL-7402 cell lines, with adriamycin as a positive control, and compounds with IC~50~ values \> 50 μM were considered to be inactive in cytotoxicity assays.

3.6. PTP1B Inhibitory Assay {#sec3dot6-marinedrugs-16-00517}
---------------------------

The PTP1B inhibitory activities of the isolates were evaluated by the method of pNPP \[[@B45-marinedrugs-16-00517]\], using sodium orthovanadate as a positive control.

4. Conclusions {#sec4-marinedrugs-16-00517}
==============

During the first chemical and biological investigation on the soft coral *S.* cf. *molesta*, ten new compounds (**1**--**5**, (+)-**9**--(+)-**11**, (+)-**13**, and **14**) and 14 known related metabolites (**6**--**8**, (--)-**9**--(--)-**11**, (±)-**12**, (--)-**13**, **15**--**19**) were obtained. Since 1975, only seven guaiane-type sesquiterpenes and two secoguaiane-type sesquiterpenes have been isolated from the soft corals of the genus *Sinularia*, including the Red Sea soft corals *S. gardineri* \[[@B46-marinedrugs-16-00517]\] and *S. terspilli* \[[@B47-marinedrugs-16-00517]\], the Formosan soft corals *S. leptoclados* \[[@B48-marinedrugs-16-00517]\] and *S. gibberosa* \[[@B5-marinedrugs-16-00517]\], the Hainan Islands soft corals *S. numerosa* \[[@B49-marinedrugs-16-00517]\] and *Sinularia* sp. \[[@B50-marinedrugs-16-00517]\], and the South China Sea soft corals *Sinularia* sp. \[[@B51-marinedrugs-16-00517],[@B52-marinedrugs-16-00517]\]. Our present study on the soft coral *S.* cf. *molesta* collected from the Paracel Islands of the South China Sea yielded two new secoguaiane-type sesquiterpenes (**1** and **2**), and three new guaiane-type sesquiterpenes (**3**--**5**), which were distinctly different from the africane-type sesquiterpenes from Moyli Island soft coral *S. intacta* \[[@B19-marinedrugs-16-00517]\]. Compounds (+)-**12** and **15** were first encountered in the genus of *Sinularia.* That enriched the specific chemo-diversities of the genus *Sinularia*. The cytotoxicities of three cembranoid diterpenes (**14**, **17**, and **18**) and PTP1B inhibitory activities of two guaiane-type sesquiterpenes (**4**, **5**) and one furanosesquiterpene (**8**) were unveiled for pharmaceutical potentials.

The following are available online at <http://www.mdpi.com/1660-3397/16/12/517/s1>. The Supplementary Materials including 1D and 2D NMR, and HRESIMS spectra of the ten new compounds, chiral HPLC chromatograms of (±)-**9**−(±)-**13**, and computational details of **1**−**5** (PDF) are available online.

###### 

Click here for additional data file.
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^13^C NMR data for compounds **1**−**5** (*δ* in ppm).

  Position   1 *^a^*       2 *^b^*       3 *^a^*       4 *^a^*        5 *^a^*
  ---------- ------------- ------------- ------------- -------------- -------------
  1          53.0, CH      59.2, CH      46.1, CH      142.8, C       89.2, C
  2          22.3, CH~2~   25.1, CH~2~   41.0, CH~2~   204.2, C       28.9, CH~2~
  3          42.0, CH~2~   42.5, CH~2~   208.7, C      51.1, CH~2~    38.3, CH~2~
  4          209.1, C      211.4, C      138.6, C      76.3, C        78.7, C
  5          203.9, C      208.0, C      174.0, C      164.6, C       162.7, C
  6          127.1, CH     127.1, CH     38.9, CH~2~   114.4, CH      127.1, CH
  7          168.7, C      170.2, C      75.6, C       165.9, C       205.3, C
  8          27.8, CH~2~   29.3, CH~2~   31.7, CH~2~   27.73, CH~2~   40.3, CH~2~
  9          36.7, CH~2~   35.9, CH~2~   30.7, CH~2~   29.4, CH~2~    27.6, CH~2~
  10         33.9, CH      35.9, CH      34.6, CH      29.1, CH       34.7, CH
  11         30.1, CH~3~   29.8, CH~3~   11.6, CH~3~   27.67, CH~3~   26.9, CH~3~
  12         74.0, C       38.6, CH      42.1, CH      39.3, CH       16.9, CH~3~
  13         28.4, CH~3~   21.5, CH~3~   17.6, CH~3~   21.7, CH~3~    
  14         28.6, CH~3~   21.3, CH~3~   17.4, CH~3~   21.3, CH~3~    
  15         16.3, CH~3~   20.3, CH~3~   8.3, CH~3~    19.6, CH~3~    
  1-OCH~3~                                                            49.6, CH~3~

*^a^* Recorded in CDCl~3~ at 125 MHz; *^b^* Recorded in methanol-*d*~4~ at 125 MHz.
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###### 

^1^H NMR data for compounds **1**−**5** (*δ* in ppm, *J* in Hz).

  Position   1 *^a^*         2 *^b^*            3 *^a^*          4 *^a^*                5 *^a^*
  ---------- --------------- ------------------ ---------------- ---------------------- ---------------
  1          2.86, m         2.37, overlap      2.08, overlap                           
  2          1.59, m         1.90, m            2.03, d (19.5)                          2.07, m
                             1.79, m            2.54, overlap                           1.70, overlap
  3          2.48, m         2.43, m                             2.56, d (5.7)          1.89, m
             2.28, m                                                                    1.70, overlap
  4                                                                                     
  5                                                                                     
  6          6.22, s         5.83, br d (1.8)   2.73, d (19.6)   6.11, s                6.15, s
                                                2.54, overlap                           
  7                                                                                     
  8          2.56, m         2.50, m            1.74, overlap    2.41, dt (11.2, 2.2)   2.77, m
             2.38, m         2.34, overlap                       2.37, m                2.50, m
  9          2.19, m         1.69, overlap      1.62, m          1.79, m                2.16, m
             1.08, m                                             1.65, m                1.43, m
  10         2.10, m         1.69, overlap      2.08, overlap    2.99, m                2.30, m
  11         2.12, s         2.10, s            1.66, s          1.50, s                1.32, s
  12                         2.36, overlap      1.71, overlap    2.51, m                0.95, d (7.1)
  13         1.38, s         1.09, d (6.9)      1.00, d (7.0)    1.12, d (6.9)          
  14         1.38, s         1.08, d (6.8)      0.99, d (7.0)    1.12, d (6.9)          
  15         0.80, d (6.7)   1.11, d (6.6)      0.65, d (7.1)    1.03, d (7.0)          
  1-OCH~3~                                                                              3.12, s

*^a^* Recorded in CDCl~3~ at 500 MHz; *^b^* Recorded in methanol-*d*~4~ at 500 MHz.

marinedrugs-16-00517-t003_Table 3

###### 

^1^H and ^13^C NMR data for compound **14** (*δ* in ppm, *J* in Hz).

  -------------------------------------------------------
  Position         *δ* ~H~ *^a^*          *δ* ~C~ *^b^*
  ---------------- ---------------------- ---------------
  1                2.30, br t (10.4)      41.5, CH

  2                3.58, dd (10.8, 4.4)   32.1, CH~2~

  2.75, d (15.2)                          

  3                                       160.4, C

  4                                       115.7, C

  5                6.75, s                108.8, CH

  6                                       152.5, C

  7                4.53, s                75.9, CH

  8                                       73.7, C

  9                2.60, m\               42.7, CH~2~
                   1.80, m                

  10               4.95, dd (10.8, 4.9)   78.1, CH

  11               6.10, s                154.6, CH

  12                                      129.7, C

  13               5.51, dd (11.2, 4.9)   66.9, CH

  14               2.60, m\               36.2, CH~2~
                   1.89, td (13.1, 4.8)   

  15                                      148.6, C

  16               4.81, d (6.1)          110.7, CH~2~

  17               1.80, s                20.8, CH~3~

  18                                      163.9, C

  19               1.41, s                18.8, CH~3~

  20                                      170.1, C

  21                                      170.5, C

  22               1.98, s                21.1, CH~3~

  18-OCH~3~        3.88, s                52.0, CH~3~
  -------------------------------------------------------

*^a^* Recorded in CDCl~3~ at 500 MHz; *^b^* Recorded in CDCl~3~ at 125 MHz.

[^1]: These authors contributed equally to this paper.
